3,344 Shares in Stryker Corporation $SYK Bought by Pure Financial Advisors LLC

Pure Financial Advisors LLC acquired a new stake in Stryker Corporation (NYSE:SYK) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 3,344 shares of the medical technology company’s stock, valued at approximately $1,053,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Gables Capital Management Inc. acquired a new position in Stryker during the second quarter worth approximately $25,000. Kilter Group LLC bought a new stake in Stryker in the 2nd quarter valued at $25,000. Godfrey Financial Associates Inc. acquired a new stake in Stryker during the 4th quarter valued at $26,000. Sankala Group LLC acquired a new position in shares of Stryker in the fourth quarter valued at $26,000. Finally, Compass Financial Management LLC bought a new position in shares of Stryker in the second quarter valued at about $27,000. 77.09% of the stock is owned by institutional investors.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the transaction, the director owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Debra King sold 826 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. This trade represents a 11.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 351,267 shares of company stock valued at $118,197,701 over the last ninety days. 4.60% of the stock is owned by corporate insiders.

Stryker Stock Performance

Shares of NYSE:SYK opened at $330.08 on Thursday. The company’s 50 day simple moving average is $328.37 and its 200 day simple moving average is $331.72. The stock has a market capitalization of $126.61 billion, a price-to-earnings ratio of 34.21, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, research analysts predict that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

Analysts Set New Price Targets

A number of brokerages recently commented on SYK. Argus set a $370.00 price target on shares of Stryker in a research note on Thursday, July 9th. BMO Capital Markets began coverage on Stryker in a report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price target for the company. Citigroup reaffirmed a “buy” rating on shares of Stryker in a report on Thursday, August 13th. Piper Sandler reduced their target price on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Finally, Needham & Company LLC dropped their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.